 Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration FDA acknowledged receipt of the resubmission of TLANDO New Drug Application NDA, the Companys oral testosterone product candidate for testosterone replacement therapy TRT in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. TLANDO is part of Lipocines TRT franchise of development candidates. The FDA has assigned a Prescription Drug User Fee Act PDUFA goal date of August 28, 2020. The NDA incorporates the reanalysis of existing data based on written feedback to address the single remaining deficiency discussed in the Post Action Meeting with the FDA. 